Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.
about
Evolving concepts in cancer therapy through targeting sphingolipid metabolismThe impact of sphingosine kinase-1 in head and neck cancer.Re-configuration of sphingolipid metabolism by oncogenic transformation.Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.Discovery and evaluation of inhibitors of human ceramidase.Interdiction of sphingolipid metabolism to improve standard cancer therapies.Apoptotic sphingolipid ceramide in cancer therapy.Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin BMesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.Acid ceramidase as a therapeutic target in metastatic prostate cancer.Acid ceramidase induces sphingosine kinase 1/S1P receptor 2-mediated activation of oncogenic Akt signaling.Molecular targeting of acid ceramidase: implications to cancer therapy.Death receptors as targets for anti-cancer therapy.Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapyTargeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.Targeting the Fas/FasL signaling pathway in cancer therapy.Sphingolipids in the DNA damage response.Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2.Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide.Fas ligand gene transfer effectively induces apoptosis in head and neck cancer cells.Fragment-Based Hologram QSAR Studies on a Series of 2,4-Dioxopyrimidine-1-Carboxamides As Highly Potent Inhibitors of Acid CeramidaseAutophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide.Improved synthesis of a fluorogenic ceramidase substrate.Adenoviral type 35 and 26 vectors with a bidirectional expression cassette in the E1 region show an improved genetic stability profile and potent transgene-specific immune response.Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer.Cytotoxic Activity and Structure Activity Relationship of Ceramide Analogues in Caki-2 and HL-60 Cells.Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges.
P2860
Q26863646-5EE71900-C280-40FB-894B-FAE1F01F0C9BQ33649748-6FD70283-0689-496B-886F-FE10D6D1B4FEQ33649823-6B8BDA0F-774E-464A-9BFE-83907FE994CFQ33713317-05048EB7-34A0-4BE7-BFFA-3D451D1BD7B4Q34008335-7B5F26F6-4D50-4FC3-8E36-A16AE9EEFD1CQ34373466-4F2CE3F9-BA27-4F21-AB87-3AE3E549DB00Q34736760-AD391A3F-3BCC-4C1A-A63D-AAEBAAD81D85Q35009571-3015E3AC-D0FF-4614-A47F-C60B503B4214Q36063053-F5BCC7A7-89DA-44F5-8A9A-35B4FF7340C5Q36200046-56AA56FC-3E5C-405A-AF99-BB41D1164907Q36498966-820DC2E9-1345-4937-AAC0-5239CD7346AAQ36526990-FEADD2D0-BAB9-4AFF-856F-2BC8D73DE748Q36754783-4A8F7D17-5331-4175-B88C-F9D5D55E288AQ37087108-9A4F5B2C-BAEF-4FF6-9D08-23EE5AA4395EQ37239617-DCCA452B-B69D-4A4B-A848-C7825E213626Q37390893-302FE8AD-A366-4FFF-8F87-7082CCDD2AD3Q37486242-DE1D3817-29B4-49A7-9278-1B85F514D812Q37718254-8E4B688A-636A-49A3-9D6B-A16B5FD123CBQ37975245-5EE9B08C-74A3-4159-9E0D-9D3B84BBFD48Q38272799-49A6A6CE-26A1-418D-8F11-315C5A69065EQ38853452-E6D4645B-84DB-4211-8E94-06FE4BC198DFQ38885436-43469ACA-6D53-4CB9-A9C8-957DE2EE55F4Q39088175-9C199109-9F25-4D7B-8CA5-C274B54AE21CQ39545354-15510534-2CC1-4ADF-AEBA-A7DED594913EQ39556274-4F3763BC-317A-4CB1-AAB9-F29737494D77Q39614279-D5B7664E-3A17-4ACA-9783-E02BF9622CC3Q39626125-8545A30D-20AB-406F-9DD3-A0E23CCF1B01Q39695142-019E5BA6-C463-4F29-B5F0-24C089E0EF9DQ40080155-BB027E06-0C4E-4E67-B6C1-9B5C77BD6699Q41135883-3245332E-A135-4D8C-92A3-03B12F115731Q42123672-AA1358E0-005A-4ACD-BB05-47C6E93EC92AQ52593622-5CAE12A5-4B0C-480D-94C6-E9821E10968A
P2860
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Combined therapeutic use of Ad ...... neck cancers: a status report.
@ast
Combined therapeutic use of Ad ...... neck cancers: a status report.
@en
type
label
Combined therapeutic use of Ad ...... neck cancers: a status report.
@ast
Combined therapeutic use of Ad ...... neck cancers: a status report.
@en
prefLabel
Combined therapeutic use of Ad ...... neck cancers: a status report.
@ast
Combined therapeutic use of Ad ...... neck cancers: a status report.
@en
P2093
P2860
P356
P1433
P1476
Combined therapeutic use of Ad ...... neck cancers: a status report
@en
P2093
Bielawska A
El-Zawahri A
ElOjeimy S
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700965
P577
2006-06-09T00:00:00Z